Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

被引：12

作者：

Watts, Justin ^{[1
]}

Baer, Maria R. ^{[2
]}

Yang, Jay ^{[3
]}

Dinner, Shira ^{[4
]}

Lee, Sangmin ^{[5
]}

Seiter, Karen ^{[6
]}

Prebet, Thomas ^{[7
]}

Schiller, Gary J. ^{[8
]}

Ferrell, Paul Brent, Jr. ^{[9
]}

Dao, Kim-Hien ^{[10
]}

Kantarjian, Hagop M. ^{[11
]}

Kelly, Patrick ^{[12
]}

Li, Ping ^{[12
]}

Sweeney, Jennifer ^{[12
]}

Watson, Courtney ^{[12
]}

Mohamed, Hesham ^{[13
]}

Cortes, Jorge E. ^{[11
]}

机构：

[1] Univ Miami, Miami, FL USA

[2] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA

[3] Karmanos Canc Inst, Detroit, MI USA

[4] Northwestern Univ, Chicago, IL 60611 USA

[5] Weill Cornell Med, Div Hematol & Oncol, New York, NY USA

[6] New York Med Coll, Hawthorne, NY USA

[7] Yale Canc Ctr, New Haven, CT USA

[8] Ronald Regan Univ Calif Los Angeles, Med Ctr, Santa Monica, CA USA

[9] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA

[10] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[11] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[12] Forma Therapeut Inc, Watertown, MA USA

[13] Forma Therapeut Inc, Princeton, NJ USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-114263

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1453

引用

页数：5

共 50 条

[1] A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Watts, Justin M.
Baer, Maria R.
Lee, Sangmin
Yang, Jay
Dinner, Shira Naomi
Prebet, Thomas
Schiller, Gary J.
Seiter, Karen
Ferrell, Paul Brent
Kelly, Patrick Francis
Li, Ping
Sweeney, Jennifer
Watson, Courtney
Mohamed, Hesham
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[2] FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study
Cortes, Jorge E.
Watts, Justin
Prebet, Thomas
Schiller, Gary J.
Lee, Sangmin
Yang, Jay
Wang, Eunice S.
Dinner, Shira
Ferrell, Paul Brent, Jr.
Donnellan, Will
Jonas, Brian A.
Wei, Andrew H.
Montesinos, Pau
Sangerman, Montserrat Arnan
Kelly, Patrick
Li, Ping
Sweeney, Jennifer
Watson, Courtney
Mohamed, Hesham
Baer, Maria R.
BLOOD, 2018, 132
[3] Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study
Watts, Justin M.
Baer, Maria R.
Yang, Jay
Prebet, Thomas
Lee, Sangmin
Schiller, Gary J.
Dinner, Shira
Pigneux, Arnaud
Montesinos, Pau
Wang, Eunice S.
Seiter, Karen
Wei, Andrew H.
De Botton, Stephane
Sangerman, Montserrat Arnan
Donnellan, William B.
Jonas, Brian A.
Ferrell, Paul Brent, Jr.
Dao, Kim-Hien
Kelly, Patrick
Sweeney, Jennifer
Forsyth, Sanjeev
Guichard, Sylvie
Brevard, Julie
Henrick, Patrick
Mohamed, Hesham
Cortes, Jorge E.
BLOOD, 2019, 134
[4] Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine
Cortes, Jorge E.
Wang, Eunice S.
Watts, Justin M.
Lee, Sangmin
Baer, Maria R.
Dao, Kim-Hien
Dinner, Shira
Yang, Jay
Donnellan, William B.
Schwarer, Anthony P.
Recher, Christian
Kelly, Patrick
Sweeney, Jennifer
Brevard, Julie
Henrick, Patrick
Forsyth, Sanjeev
Guichard, Sylvie
Mohamed, Hesham
Wei, Andrew H.
BLOOD, 2019, 134
[5] PHASE 1 STUDY OF FT-2102, AN INHIBITOR OF MUTANT IDH1, IN PATIENTS WITH RELAPSED/REFRACTORY IDH1 MUTANT GLIOMAS: PRELIMINARY SAFETY AND CLINICAL ACTIVITY
De la Fuente, Macarena I.
Colman, Howard
Rosenthal, Mark
Van Tine, Brian A.
Fonkem, Ekokobe
Walbert, Tobias
Milhem, Mohammed
Lipford, Kate
Forsyth, Sanjeev
Guichard, Sylvie
Brevard, Julie
Mikhailov, Yelena
Thomson, Blythe
Monga, Varun
NEURO-ONCOLOGY, 2019, 21 : 25 - 25
[6] A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome
Courtney D. DiNardo
Andreas Hochhaus
Mark G. Frattini
Karen Yee
Thomas Zander
Alwin Krämer
Xueying Chen
Yan Ji
Nehal S. Parikh
Joanne Choi
Andrew H. Wei
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 1145 - 1158
[7] A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome
DiNardo, Courtney D.
Hochhaus, Andreas
Frattini, Mark G.
Yee, Karen
Zander, Thomas
Kraemer, Alwin
Chen, Xueying
Ji, Yan
Parikh, Nehal S.
Choi, Joanne
Wei, Andrew H.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 1145 - 1158
[8] Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m ND-AML Treated with Ivo plus AZA in the AGILE Study
Doehner, Hartmut
Marchione, Dylan M.
Choe, Sung
Montesinos, Pau
Recher, Christian
Vives, Susana
Zarzycka, Ewa
Wang, Jianxiang
Cerchione, Claudio
Heuser, Michael
Calado, Rodrigo T.
Schuh, Andre C.
Yeh, Su-Peng
De la Fuente, Adolfo
Hui, Jianan
Patel, Prapti
Gianolio, Diego A.
Daigle, Scott R.
DiNardo, Courtney D.
De Botton, Stephane
BLOOD, 2022, 140
[9] Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
de Botton, Stephane
Fenaux, Pierre
Yee, Karen
Recher, Christian
Wei, Andrew H.
Montesinos, Pau
Taussig, David C.
Pigneux, Arnaud
Braun, Thorsten
Curti, Antonio
Grove, Carolyn
Jonas, Brian A.
Khwaja, Asim
Legrand, Ollivier
Peterlin, Pierre
Arnan, Montserrat
Blum, William
Cilloni, Daniela
Hiwase, Devendra K.
Jurcic, Joseph G.
Krauter, Juergen
Thomas, Xavier
Watts, Justin M.
Yang, Jay
Polyanskaya, Olga
Brevard, Julie
Sweeney, Jennifer
Barrett, Emma
Cortes, Jorge
BLOOD ADVANCES, 2023, 7 (13) : 3117 - 3127
[10] IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome
Lin, Jiang
Yao, Dong-ming
Qian, Jun
Chen, Qin
Qian, Wei
Li, Yun
Yang, Jing
Wang, Cui-zhu
Chai, Hai-yan
Qian, Zhen
Xiao, Gao-fei
Xu, Wen-rong
ANNALS OF HEMATOLOGY, 2012, 91 (04) : 519 - 525

← 1 2 3 4 5 →